Your browser doesn't support javascript.
loading
Rapid detection of Nipah virus using the one-pot RPA-CRISPR/Cas13a assay.
Miao, Jing; Zuo, Lulu; He, Dongmei; Fang, Zhixin; Berthet, Nicolas; Yu, Chao; Wong, Gary.
Afiliación
  • Miao J; Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shangha 200031, China; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Zuo L; Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shangha 200031, China; University of Chinese Academy of Sciences, Beijing 100049, China.
  • He D; Institute of Pathogenic Microorganisms, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 510440, China.
  • Fang Z; Biosafety Laboratory, Guangdong Second Provincial General Hospital, Guangzhou 510317, China.
  • Berthet N; Centre for Microbes, Development, and Health, Institut Pasteur of Shanghai, Unit of Discovery and Molecular Characterization of Pathogens, Chinese Academy of Sciences, Shanghai 200031, China; Institut Pasteur, Unité Environnement et Risque Infectieux, Cellule d'Intervention Biologique d'Urgence, Uni
  • Yu C; Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shangha 200031, China. Electronic address: ychao@ips.ac.cn.
  • Wong G; Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shangha 200031, China. Electronic address: garyckwong@ips.ac.cn.
Virus Res ; 332: 199130, 2023 07 15.
Article en En | MEDLINE | ID: mdl-37178792
Nipah virus (NiV) is a zoonotic pathogen with airborne transmission and high case fatality rates in humans. There is currently no treatment or vaccine against NiV infection approved for humans or animals, therefore early diagnosis is the key to control any potential outbreaks. In this study, we developed an optimized one-pot assay using recombinase polymerase amplification (RPA) coupled to CRISPR/Cas13a for the molecular detection of NiV. The one-pot RPA-CRISPR/Cas13a assay for NiV detection was specific and did not cross-react against other selected (re)-emerging pathogens. The sensitivity of the one-pot RPA-CRISPR/Cas13a assay for NiV detection can detect as little as 103 cp/µL of total synthetic NiV cDNA. The assay was then validated with simulated clinical samples. The results for the one-pot RPA-CRISPR/Cas13a assay could be visualized with either fluorescence or lateral flow strips for convenient clinical or field diagnostics, providing a useful supplement to the gold-standard qRT-PCR assay for detecting NiV detections.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Virus Nipah / Recombinasas Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Animals / Humans Idioma: En Revista: Virus Res Asunto de la revista: VIROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Virus Nipah / Recombinasas Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Animals / Humans Idioma: En Revista: Virus Res Asunto de la revista: VIROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China